tbuckley/cabot-search huggingface dataset:
FRI0294 Prevalence and risk factors for memory dysfunction in systemic lupus erythematosus patients
Authors: S. S. Shudim, M. S. Mohamed Said, S. S. Shaharir, N. C.T. Kong
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Neuropsychiatric manifestations in systemic lupus erythematosus (SLE) is common and affects some 45 - 70% of SLE patients during the course of this chronic relapsing remitting multisystem autoimmune disease. Less well known is the prevalence of the more subtle memory dysfunction - with 4 Sub-domains - which together constitutes part of the cognitive process. <h3>Objectives</h3> This study aimed to determine the prevalence of memory dysfunction and its associated risk factors among SLE patients on follow up at both the Rheumatology and Nephrology/SLE clinics, UKM Medical Center. <h3>Methods</h3> This was a prospective, cross-sectional study which recruited SLE patients without a past history of overt central nervous system (CNS) lupus. These patients were interviewed and assessed using the Wechsler Memory Scale-4<sup>th</sup> edition UK version (WMS-IV<sup>UK</sup>). Based on their WMS-IV<sup>UK</sup> scores, they were then categorized as having impaired memory or non-impaired memory. Their SLE disease activities were determined by clinical features together with blood and urine parameters. <h3>Results</h3> A total of 54 patients were screened, 40 fulfilled the criteria but only 15 consented to participate. There were 14 females and only one male. Majority of them (n=12, 80%) had tertiary education. Memory dysfunction was identified in 7/15 (46.7%). There was a significant association between memory dysfunction and lower serum thyroxine levels (p=0.027*). No associations were found between memory dysfunction and any of the lupus autoantibodies nor complement levels nor with the use of corticosteroids and other immunomodulatory treatment. The score in 3 out of 4 sub-domains of memory were significantly different between non-impaired and impaired memory group (visual memory, p=0.004**, immediate memory, p= 0.009**; delayed memory, p=0.012*). The auditory memory was associated with lower education level (p=0.025*), cumulative number of organ systems involved (p=0.012*) and cumulative number of treatments (p=0.029*). Whereas visual memory was influenced by disease duration (p=0.016*). <h3>Conclusions</h3> There is a high prevalence of hitherto under-recognized memory dysfunction amongst SLE patients. The risk factors for these were included serum thyroxine, disease duration, cumulative number of organ systems involvement and cumulative number of treatments. However, the small number of patients studied does not permit these results to be generalized to the rest of our SLE patients. A larger study is indicated. <b>Disclosure of Interest</b>: None Declared
Leap of Faith — Medicare's New Physician Payment System
Authors: Jonathan Oberlander, Miriam J. Laugesen
Journal: New England Journal of Medicine (2015)

Interview with Dr. Jonathan Oberlander on the outlook for Medicare's new physician payment system. (08:15)Download Medicare's new payment system reflects the movement toward value-based payment, which is built on the view that we can contain costs only by eliminating fee-for-service payment. But there are important problems with this belief and the reforms it inspires.
Transmission of Hepatitis B Virus to Multiple Patients from a Surgeon without Evidence of Inadequate Infection Control
Authors: Rafael Harpaz, Lorenz Von Seidlein, Francisco M. Averhoff, Michael P. Tormey, Saswati D. Sinha, Konstantina Kotsopoulou, Stephen B. Lambert, Betty H. Robertson, James D. Cherry, Craig N. Shapiro
Journal: New England Journal of Medicine (1996)

Although about 1 percent of surgeons are infected with hepatitis B virus (HBV), transmission from surgeons to patients is thought to be uncommon. In July 1992, a 47-year-old woman became ill with acute hepatitis B after undergoing a thymectomy in which a thoracic-surgery resident who had had acute hepatitis B six months earlier assisted.To determine whether the surgeon transmitted HBV to this patient and others, we conducted chart reviews, interviews, and serologic testing of thoracic-surgery patients at the two hospitals where the surgeon worked from July 1991 to July 1992. Hepatitis B surface antigen (HBsAg) subtypes and DNA sequences from the surgeon and from infected patients were determined.Of 144 susceptible patients in whose surgery the infected surgeon participated, 19 had evidence of recent HBV infection (13 percent). One of the hospitals was selected for additional study, and none of the 124 susceptible patients of the other thoracic surgeons at this hospital had evidence of recent HBV infection (relative risk, infinity; 95 percent confidence interval, 4.7 to infinity). No evidence was found for any common source of HBV other than the infected surgeon. The HBsAg subtype and the partial HBV DNA sequences from the surgeon were identical to those in the infected patients. Transmission of the infection was associated with cardiac transplantation (relative risk, 4.9; 95 percent confidence interval, 1.5 to 15.5) but not with other surgical procedures. The surgeon was positive for hepatitis B e antigen and had a high serum HBV DNA concentration (15 ng per milliliter). Our investigations identified no deficiencies in the surgeon's infection-control practices.In this outbreak there was surgeon-to-patient HBV transmission despite apparent compliance with recommended infection-control practices. We could not identify any specific events that led to transmission.
EPIDEMIOLOGY OF NEW-ONSET POST-CABG ATRIAL FIBRILLATION: A LARGE MULTI-CENTER STUDY
Authors: Giovanni Filardo, Ralph Damiano, Gorav Ailawadi, Vinod Thourani, Benjamin Pollock, Danielle Sass, Teresa K. Phan, Briget da Graca
Journal: Journal of the American College of Cardiology (2016)
AB0815 Fracture Risk in A Sample of Tunisian Women Using FRAX Tool
Authors: H. Sahli, M. Slouma, S. Rekik, M. Elleuch, A. Haj SAlah, B. Zouari, E. Cheour
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> This is the second part of the study about the prevalence of osteoporotic fractures in the Tunisian population and which includes 1311 women, aged 64.07±9.31 years, which revealed the presence of fractures in 212 women (16.2%), mainly represented by vertebral fractures (59.83%). What about the subsequent risk of fracture in this cohort? [1] <h3>Objectives</h3> The aim of this study was to determine the probability of fracture predicted by Frax (fracture risk assessment tool) comparing women with and without history of fracture. <h3>Methods</h3> A prospective and comparative cohort of 111 postmenopausal women with medical history of fracture (G1) and 111 postmenopausal women without medical history of fracture (G2), matched for age, race and body mass index were included in the study. BMD was measured by dual energy X-ray absorptiometry (DXA) at lumbar spine and femoral neck. We calculated Frax values for hip in both groups and evaluated osteoporotic fracture in this cohort. Both statistical and descriptive analyses were performed. <h3>Results</h3> The mean age was 65.92±9.48 years in G1 and 64.55±9.98 years in G2 (p=0.296). BMI values in G1 and G2 were respectively 29.18±4.96 and 28.82±4.62 kg/m<sup>2</sup> (0.573). Mean values of FRAX TOOL for major osteoporotic fracture in G1 and G2 were respectively 1.507±0.788 and 0.764±0.390 (p=0.000). And, mean Frax values for hip fracture in G1 and G2 were 0.384±0.504 and 0.161±0.232 respectively (p=0.000). The discriminative capacity of FRAX analyzed by the Area Under Curve (AUC), Receiver Operating Characteristics (ROC). The AUC were 0.873 (CI 95%; 0.827-0.919) for major osteoporotic fracture and 0.68 (CI 95%; 0.612-0.752) for hip fracture. Therefore odds ratio for major osteoporotic and hip fracture were 18.2 and 3.1. <h3>Conclusions</h3> Our study confirmed the significant increase of fracture risk in patients with a history of fracture thereby enhancing the need to strengthen prevention of osteoporosis fracture in our population. Furthermore, our study demonstrated that in Tunisian female patients, cut-off FRAX values are 0.873 and 0.68 for major osteoporotic fracture and hip fracture respectively <h3>References</h3> Sahli H, Testouri N, Chihaoui MB, Salah AH, Cheour E, Meddeb N, Zouari B, Sellami S. Bone mineral density in healthy Tunisian women. Maturitas. 2009 Jul 20;63(3):227-32 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5697
Improving surveillance of sexually transmitted infections using mandatory electronic clinical reporting: the genitourinary medicine clinic activity dataset, England, 2009 to 2013
Authors: E  J Savage, H Mohammed, G Leong, S Duffell, G Hughes
Journal: Eurosurveillance (2014)

A new electronic surveillance system for sexually transmitted infections (STIs) was introduced in England in 2009. The genitourinary medicine clinic activity dataset (GUMCAD) is a mandatory, disaggregated, pseudo-anonymised data return submitted by all STI clinics across England. The dataset includes information on all STI diagnoses made and services provided alongside demographic characteristics for every patient attendance at a clinic. The new system enables the timely analysis and publication of routine STI data, detailed analyses of risk groups and longitudinal analyses of clinic attendees. The system offers flexibility so new codes can be introduced to help monitor outbreaks or unusual STI activity. From January 2009 to December 2013 inclusive, over twenty-five million records from a total of 6,668,648 patients of STI clinics have been submitted. This article describes the successful implementation of this new surveillance system and the types of epidemiological outputs and analyses that GUMCAD enables. The challenges faced are discussed and forthcoming developments in STI surveillance in England are described.
Deep-Vein Thrombosis
Authors: Eran E. Weinmann, Edwin W. Salzman
Journal: New England Journal of Medicine (1994)

Credit for fundamental studies leading to our current understanding of deep-vein thrombosis should be given to Bauer, who used phlebography to diagnose deep-vein thrombosis complicating fractures of the tibia,1 and to Sevitt and Gallagher for their autopsy-based studies of the prevalence of venous thromboembolism in patients with other injuries2,3. The development of objective methods for the diagnosis of deep-vein thrombosis has facilitated the investigation of its natural history and has provided a rational basis for its prevention and treatment.DiagnosisMost venous thrombi are clinically silent when they are first detectable by objective methods,2,4 probably because they . . .
985 VIRAL HEPATITIS SEROEPIDEMIOLOGY AMONG ACTIVE INJECTING DRUG USERS IN ATHENS, GREECE: A 10-YEAR RETROSPECTIVE STUDY OF THE GREEK ORGANIZATION AGAINST DRUGS
Authors: I. Elefsiniotis, M. Sheka, S. Patrinos, E. Argyropoulos, T. Papadopoulos, A. Drimousi, G. Saroglou
Journal: Journal of Hepatology (2012)
Abstract 3078: Mifepristone suppresses triple-negative breast cancer cell growth via miR-153 mediated down-regulation of KLF5 expression.
Authors: Rong Liu, Ceshi Chen
Journal: Cancer Research (2013)

Abstract Triple-negative breast cancer (TNBC) is one of the most malignant breast cancers without effective therapeutic approaches currently. It is reported that KLF5 is over-expressed in TNBC; and KLF5 depletion suppresses TNBC cell proliferation, cell survival and tumor growth in vivo significantly, which implies that KLF5 may be a therapeutic target for TNBC treatment. As a progesterone receptor antagonist, mifepristone (MIF) has been found to have anti-tumor activity in multiple hormone-dependent cancers, including luminal type breast cancers. Interestingly, we found that MIF is also able to suppress KLF5 protein expression in TNBC cell and inhibit TNBC cell growth in vitro and in vivo. We further demonstrated that MIF does not suppress KLF5 mRNA expression at all, but down-regulates KLF5 protein level via up-regulating miR-153 expression in TNBC cells. We found miR-153 mimics can down-regulates KLF5 protein level in TNBC cells similar to MIF does; and consistently, miR-153 inhibitor rescues MIF-induced down-regulation of KLF5 protein expression. Taken together, our findings suggest that MIF is able to inhibit TNBC growth possibly via suppressing KLF5 expression; and our research may provide a new possible chemotherapeutic for the treatment of TNBC. Citation Format: Rong Liu, Ceshi Chen. Mifepristone suppresses triple-negative breast cancer cell growth via miR-153 mediated down-regulation of KLF5 expression. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3078. doi:10.1158/1538-7445.AM2013-3078
FRI0001 Good Response after Three Months of Treatment with Biologic Agents May PREDICT Long-Term Efficacy of Biologic Treatment in Patients with Rheumatoid Arthritis
Authors: C.E. Lampropoulos, F. Orfanos, V.-K. Bournia, T. Karatsourakis, D. Lekaditi, K. Mavragani, D. Pikazis, M. Manousakis, A. Tzioufas, H.M. Moutsopoulos, P.G. Vlachoyiannopoulos
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatoid arthritis (RA) is an autoimmune disease with involvement of small and large joints. Biologic agents (BAs) represent treatment options if disease is not adequately controlled by DMARDs. Prognostic factors that may predict good clinical response to treatment and long-term efficacy need to be identified in these patients. <h3>Objectives</h3> To estimate the predictive value of early good response, after 3 months of biologic treatment, in long-term efficacy and the level of disease activity in patients with RA. <h3>Methods</h3> This is a retrospective study of 1.494 patients9 files (1.173 women and 321 men, mean age at disease initiation 48.9 years). Demographic and clinical data were recorded during every patient9s visit. There were 355 patients with initiation of biologic treatment during their follow-up in our department. Patients with less than 12 months administration of their first BA were excluded from further analysis. Disease activity was classified by DAS-28 score at 3, 6 and 12 months of treatment. Effectiveness of BAs was analyzed, taken in to account the EULAR criteria for response to treatment. <h3>Results</h3> Two hundred forty seven patients with more than 12 months therapy with BAs were included in this analysis. Patients with good response after 3 months of treatment (DAS-28 &lt;3.2, &gt;1.2 variation between initial and final DAS-28), compared to patients with inadequate response, were 5 times more likely to achieve satisfactory response (remission or low disease activity) after 1 year of BAs administration (OR=5.15, 95% CI 2.84-9.31, p-value &lt;0.0001). After adjustment for sex, age, type of joints and presence of extra-articular manifestations, the probability for good response remained similar (OR=4.73, 95% CI 2.53-8.84, p-value &lt;0.0001). Further analysis was performed separately in incident (n=121) and prevalent cases (n=126). In the first group, patients with good response after 3 months of treatment were 6 times more likely to have similar response after one year of BAs (OR=6.27, 95% CI 2.57-15.33, p-value &lt;0.0001) and 5 times more likely after adjustment to the aforementioned factors (OR=4.92, 95% CI 1.91-12.68, p-value =0.001). In the second group of prevalent cases, the prognostic value of early good response to treatment was similar (OR=4.45, 95% CI 1.99-9.93, p-value &lt;0.0001 and OR=5.05, 95% CI 2.08-12.27, p-value &lt;0.0001 after adjustment respectively). <h3>Conclusions</h3> Early good response after 3 months of BAs administration may adequately predict a satisfactory long-term efficacy of biologic treatment in patients with RA. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4667
Abstract 2040: The Mre11 nuclease is critical for sensitivity of cells to Chk1 inhibition
Authors: Ruth H. Thompson, Ryan E. Montano, Alan R. Eastman
Journal: Cancer Research (2012)

Abstract The Chk1 kinase is required for the arrest of cell cycle progression when DNA is damaged, thereby providing time for cells to repair their DNA and recover. Chk1 also stabilizes stalled replication forks. As a consequence, many Chk1 inhibitors have been developed and tested for their potential to enhance DNA damage-induced tumor cell killing. However, inhibition of Chk1 alone, without any additional exogenous agent, can be cytotoxic. Using the novel Chk1 inhibitor MK-8776 (previously known as SCH900776), we screened a panel of cell lines and found that some are killed rapidly at low concentrations while other cell lines continue to grow in the presence of much higher concentrations. Understanding the underlying mechanisms of this sensitivity is critical for defining which patients might respond best to therapy with Chk1 inhibitors. We have investigated the mechanism of sensitivity in U2OS osteosarcoma cells. Upon incubation with MK-8776, single-stranded DNA regions (ssDNA) and double-strand breaks (DSB) begin to appear within 6 h. These DSB have been attributed to the structure-specific DNA endonuclease, Mus81. The Mre11/Rad50/Nbs1 (MRN) complex is known to be responsible for the resection of DSB to ssDNA. However, we show that inhibition of the Mre11 nuclease activity leads to a decrease not only in the amount of ssDNA following Chk1 inhibition, but also in the formation of DSB, suggesting that DSB arise as a consequence of ssDNA formation. These findings were corroborated by the discovery that Mre11-deficient ATLD1 cells are highly resistant to MK-8776 and form neither ssDNA nor DSB following treatment, but once complimented with exogenous Mre11, the cells accumulate both ssDNA and DSB when incubated with MK-8776. Inhibition of Chk1 also leads to aberrant activation of Cdc25A and Cdk2, and our findings suggest that Mre11 provides the link between Cdk2 activation and Mus81. We propose that the variable sensitivity of cell lines to Chk1 inhibition reflects defects in this pathway. These data highlight a novel role for Mre11 in the production of DSB and may help define which tumors are more sensitive to MK-8776 alone or in combination with DNA damaging agents. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2040. doi:1538-7445.AM2012-2040
Abstract 1570: Thermal ablation improves oxygenation in remaining viable tumor
Authors: Robert J. Griffin, Beata D. Przybyla, Jonathon D. Pagan, Xin Chen, Gal Shafirstein, Jessica S. Webber, Eduardo G. Moros
Journal: Cancer Research (2011)

Abstract To increase the use and effectiveness of thermal therapy of various solid cancers, it is necessary to understand how tumor remaining viable after ablation responds and repairs. Tumor oxygenation and angiogenesis are critical for tumor recurrence and therefore we are studying the changes in tumor oxygenation and migration pattern of endothelial progenitor cells (EPCs), one component of angiogenesis, after local thermal ablation of tumors in mice. Tumor cells in sublethal ablation zones may release a unique set of chemokines in an attempt to attract cells to repair and regrow the tumor. The location and mechanisms by which these cells are recruited to the tumor may be distinct from other methods of thermal therapy which suggests that specific targets to improve ablation outcomes may be identified. If the oxygenation is changed in tumor that remains viable after ablation, concomitant application of chemotherapy or radiation therapy may be an effective way to improve tumor control. Murine FSaII fibrosarcoma and 4T1 breast carcinoma tumors were ablated with a conductance probe or high intensity ultrasound at an average peak temperature of 60-90C for 1.5 min. One group of mice was immediately injected IV with near infrared emitting indocyanine green (ICG)-labeled EPCs, while the other group was injected with EPCs labeled with a stable in situ dye (PKH). The mice injected with ICG-labeled EPC were optically imaged at various time points up to 72 hours. These images were then compared to those of untreated tumors to observe the migration patterns of EPC in mice that had received HIFU ablation. In other mice, pimonidazole was injected 72 h post ablation and tumors were excised and stained for pimonidazole adducts as evidence of hypoxia. We routinely ablated approximately 50% of tumor tissue, leaving the other 50% peripheral tumor tissue viable. We were able to detect an increased amount of ICG signal in the tumor that received ablation ablation, when compared to controls. Histological examination revealed the presence of EPC cells in the tumor after ablation, while the control showed no signs of EPC presence. The tumor oxygenation in viable tissue after ablation was found to increase from control tumors where 27% of the tumor was pimonidazole positive to only 5% in thermally ablated tumors. The role of endothelial progenitors and tumor oxygenation changes in overall tumor response to ablation alone and combined with other modalities is being actively studied by our group. This work was supported by NIH grant CA44114 and Central Arkansas Radiation Therapy Institute. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1570. doi:10.1158/1538-7445.AM2011-1570
PET/CT Imaging of Squamoid Eccrine Ductal Carcinoma
Authors: Bin Wang, Abel D. Jarell, Jonathan L. Bingham, Grant H. Bonavia
Journal: Clinical Nuclear Medicine (2014)

Squamoid eccrine ductal carcinoma is an extremely uncommon type of eccrine carcinoma (EC). An important distinguishing feature of EC is potential for metastasis. Eccrine carcinoma has been reported to metastasize in up to 50% of cases. Despite tumor aggressivity, no recommendations for staging exist. We present the case of a 91-year-old woman with a lesion involving the left index finger confirmed to be squamoid eccrine ductal carcinoma by dermatopathologic evaluation. 18F-FDG PET/CT images revealed widespread multifocal FDG-avid metastatic disease. Although rare, staging of EC with 18F-FDG PET/CT imaging of the entire body is indicated.